These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 5545146)

  • 1. Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. II. Clustering of effective C42 complexes at individual hemolytic sites.
    Opferkuch W; Rapp HJ; Colten HR; Borsos T
    J Immunol; 1971 Feb; 106(2):407-13. PubMed ID: 5545146
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. 3. The hemolytic efficiency of human and guinea pig C2 and C4.
    Opferkuch W; Rapp HJ; Colten HR; Borsos T
    J Immunol; 1971 Apr; 106(4):927-31. PubMed ID: 4995006
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. I. Functional differences among C4 sites on cell surfaces.
    Borsos T; Rapp HJ; Colten HR
    J Immunol; 1970 Dec; 105(6):1439-46. PubMed ID: 4991793
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. IV. Formation of EAC42 by treatment of C2 with trypsin in the presence of EAC4.
    Loos M; Borsos T; Rapp HJ
    J Immunol; 1972 Sep; 109(3):434-8. PubMed ID: 5055179
    [No Abstract]   [Full Text] [Related]  

  • 5. Hemolytic efficiency of cell-bound IgM: evidence that IgM-C1 complexes activate C4 molecules not hemolytic with homologous C2--C9.
    Ejzemberg R; Borsos T
    J Immunol; 1982 Apr; 128(4):1600-2. PubMed ID: 7061844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incomplete functional deficiencies of the fourth (C4) and second (C2) components of complement in a patient with linear frontoparietal scleroderma and his family. Deficiencies determined by a gene not linked to human leukocyte antigen system.
    Venneker GT; van Meegen M; de Kok-Nazaruk M; Hulsmans RF; de Waall LP; Bos JD; Asghar SS
    Exp Clin Immunogenet; 1996; 13(2):104-11. PubMed ID: 9063702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of functional activity of components and factors of the human complement system].
    Kozlov LV
    Vopr Med Khim; 2002; 48(6):624-31. PubMed ID: 12698564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of consumption kinetics of the C4 and C2 components of complement by immune complexes "in vitro" (author's transl)].
    Roncato M; Maillet F; Peltier AP
    Pathol Biol (Paris); 1981 Feb; 29(2):95-9. PubMed ID: 7015243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein.
    Daha MR; van Es LA
    J Immunol; 1980 Nov; 125(5):2051-4. PubMed ID: 6903579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classical pathway complement activity in Familial Mediterranean fever.
    Mkrtchyan GM; Boyajyan AS; Ayvazyan AA; Beglaryan AA
    Clin Biochem; 2006 Jul; 39(7):688-91. PubMed ID: 16631629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classical pathway complement activity in schizophrenia.
    Hakobyan S; Boyajyan A; Sim RB
    Neurosci Lett; 2005 Feb; 374(1):35-7. PubMed ID: 15631892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of bovine complement levels measured by radial hemolysis to correlate with tube titration.
    Nielsen K; Rosenbaum B; Harper S; Adams LG; Williams JD
    Am J Vet Res; 1983 Oct; 44(10):1935-7. PubMed ID: 6416118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage maturation: differences in complement secretion by marrow, monocyte, and tissue macrophages detected with an improved hemolytic plaque assay.
    Alpert SE; Auerbach HS; Cole FS; Colten HR
    J Immunol; 1983 Jan; 130(1):102-7. PubMed ID: 6336622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies of an additional kindred with hereditary deficiency of the second component of human complement (C2) and description of a new method for the quantitation of C2.
    Cooper NR; ten Bensel R; Kohler PF
    J Immunol; 1968 Dec; 101(6):1176-82. PubMed ID: 5749189
    [No Abstract]   [Full Text] [Related]  

  • 16. Complement synthesis by guinea pig peritoneal macrophages: failure to detect chemical carcinogens.
    Kunke KS; Strunk RC
    J Natl Cancer Inst; 1981 Jan; 66(1):141-6. PubMed ID: 6935455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which complement assays and typings are necessary for the diagnosis of complement deficiency in patients with lupus erythematosus? A study of 25 patients.
    Boeckler P; Meyer A; Uring-Lambert B; Goetz J; Cribier B; Hauptmann G; Lipsker D
    Clin Immunol; 2006 Nov; 121(2):198-202. PubMed ID: 16987709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory detection of complement activation and complement deficiencies.
    Lint TF
    Am J Med Technol; 1982 Sep; 48(9):743-8. PubMed ID: 6814254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrastructural localization of the third and fourth components of complement on complement-cell complexes.
    Mardiney MR; Müller-Eberhard HJ; Feldman JD
    Am J Pathol; 1968 Aug; 53(2):253-61. PubMed ID: 5667579
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparative study of complement components in polyethylene glycol precipitated immune complexes from patients with ovarian cancer and patients with rheumatoid arthritis.
    Mooney NA; Hay FC; Poulton TA
    Clin Exp Immunol; 1983 Jun; 52(3):561-8. PubMed ID: 6603297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.